M. Kowanetz
Molecular Biology · 2005–2019
A researcher in the Science corpus: 8 papers; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.
Subfields
- Molecular Biology — 21 citations into it
Whom M. Kowanetz trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Papers from M. Kowanetz's perspective
Ordered by how strongly the researchers M. Kowanetz trusts endorse each paper. Same corpus, a different order for every researcher.
- Genomic analysis of metastasis reveals an essential role for RhoC (Nature)
- A multigenic program mediating breast cancer metastasis to bone. (Cancer Cell)
- Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis (Nature reviews. Molecular cell biology)
- SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. (Molecular Pharmacology)
- Intravital imaging of cell movement in tumours (Nature Reviews. Cancer)
- Mechanisms of TGF-β Signaling from Cell Membrane to the Nucleus
- Molecular Pathways: Next-Generation Immunotherapy—Inhibiting Programmed Death-Ligand 1 and Programmed Death-1 (Clinical Cancer Research)
- Cancer immunotherapy comes of age (Nature)
- Phosphatidylinositol 3-Kinase Function Is Required for Transforming Growth Factor β-mediated Epithelial to Mesenchymal Transition and Cell Migration* (Journal of Biological Chemistry)
- Tumor Exome Analysis Reveals Neoantigen-Specific T-Cell Reactivity in an Ipilimumab-Responsive Melanoma (Journal of Clinical Oncology)
Their papers
- TGF-beta and the Smad signaling pathway support transcriptomic reprogramming during epithelial-mesenchymal cell transition. (2005) — 644 citations
- Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. (2019) — 1,390 citations
- Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. (2019) — 822 citations
- Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab (2018) — 1,039 citations
- Atezolizumab for First‐Line Treatment of Metastatic Nonsquamous NSCLC (2018) — 3,127 citations
- Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. (2016) — 2,545 citations
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial (2016) — 4,239 citations
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients (2014) — 4,940 citations